Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIV/HCV-coinfected patients

Journal of Viral Hepatitis

Volumn 18, Issue 7, 2011, Pages

  Loko, M A ^a   Bani Sadr, F ^a,b   Winnock, M ^a   Lacombe, K ^c   Carrieri, P ^d   Neau, D ^e   Morlat, P ^a,f   Serfaty, L ^c   Dabis, F ^a   Salmon, D ^b  

^a INSERM   (France)

^b Université Paris Descartes ^*  (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

^e HÔPITAL PELLEGRIN   (France)

^f HÔPITAL SAINT ANDRÉ   (France)

Author keywords

advanced liver fibrosis; didanosine; HIV HCV coinfection; insulin resistance; lipodystrophy

Indexed keywords

ABACAVIR; BUPRENORPHINE; DIDANOSINE; EFAVIRENZ; METHADONE; NEVIRAPINE; PROTEINASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ADVANCED LIVER FIBROSIS; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CD4 LYMPHOCYTE COUNT; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE DURATION; DRUG EXPOSURE; FEMALE; GLUCOSE METABOLISM; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; INTRAVENOUS DRUG ABUSE; LIPODYSTROPHY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MITOCHONDRIAL TOXICITY; MIXED INFECTION; PRIORITY JOURNAL; VIRUS TRANSMISSION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; COINFECTION; DIDANOSINE; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; INSULIN RESISTANCE; LIPODYSTROPHY; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MITOCHONDRIA; SEX FACTORS; STAVUDINE;

EID: 79959577367     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2010.01417.x     Document Type: Article

References (42)

1. Brau N,. Update on chronic hepatitis C in HIV/HCV-coinfected patients: viral interactions and therapy. AIDS 2003; 17: 2279-2290. (Pubitemid 38147013)
2. Martinez-Sierra C, Arizcorreta A, Diaz F, et al. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 2003; 36: 491-498. (Pubitemid 36241318)
3. Zylberberg H, Pialoux G, Carnot F, Landau A, Brechot C, Pol S,. Rapidly evolving hepatitis C virus-related cirrhosis in a human immunodeficiency virus-infected patient receiving triple antiretroviral therapy. Clin Infect Dis 1998; 27: 1255-1258. (Pubitemid 29242480)
4. Bani-Sadr F, Lapidus N, Bedossa P, et al. Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors. Clin Infect Dis 2008; 46: 768-774. (Pubitemid 351321564)
5. Sulkowski MS, Mehta SH, Torbenson MS, et al. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS 2007; 21: 2209-2216. (Pubitemid 350287219)
6. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30: 1054-1058. (Pubitemid 29458296)
7. Brau N, Salvatore M, Rios-Bedoya CF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006; 44: 47-55. (Pubitemid 41772515)
8. Bani-Sadr F, Carrat F, Bedossa P, et al. Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors. AIDS 2006; 20: 525-531. (Pubitemid 43731596)
9. Bani-Sadr F, Bedossa P, Rosenthal E, et al. Does early antiretroviral treatment prevent liver fibrosis in HIV/HCV-coinfected patients? J Acquir Immune Defic Syndr 2009; 50: 234-236.
10. Bani-Sadr F, Barange K, Daoud F, et al. Persistently normal alanine aminotransferase levels in HIV/HCV-coinfected patients: the role of steatosis. HIV Med 2009; 10: 417-421.
11. Mohsen AH, Easterbrook PJ, Taylor C, et al. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut 2003; 52: 1035-1040. (Pubitemid 36765298)
12. Marine-Barjoan E, Saint-Paul MC, Pradier C, et al. Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV/hepatitis C virus co-infected patients. AIDS 2004; 18: 2163-2170. (Pubitemid 39463681)
13. Blanco F, Barreiro P, Ryan P, et al. Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance. J Viral Hepat 2011; 18 (1): 11-16.
14. Vali B, Yue FY, Jones RB, et al. HIV-specific T-cells accumulate in the liver in HCV/HIV co-infection. PLoS ONE 2008; 3: e3454.
15. Kuntzen T, Tural C, Li B, et al. Intrahepatic mRNA expression in hepatitis C virus and HIV/hepatitis C virus co-infection: infiltrating cells, cytokines, and influence of HAART. AIDS 2008; 22: 203-210.
16. Ascaso JF, Romero P, Real JT, Priego A, Valdecabres C, Carmena R,. [Insulin resistance quantification by fasting insulin plasma values and HOMA index in a non-diabetic population]. Med Clin (Barc) 2001; 117: 530-533. (Pubitemid 33100193)
17. Ryan P, Blanco F, Garcia-Gasco P, et al. Predictors of severe hepatic steatosis using abdominal ultrasound in HIV-infected patients. HIV Med 2009; 10: 53-59.
18. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-350. (Pubitemid 40439195)
19. McGovern BH, Golan Y, Lopez M, et al. The impact of cirrhosis on CD4+ T cell counts in HIV-seronegative patients. Clin Infect Dis 2007; 44: 431-437. (Pubitemid 46147629)
20. Gandhi RT,. Cirrhosis is associated with low CD4+ T cell counts: implications for HIV-infected patients with liver disease. Clin Infect Dis 2007; 44: 438-440. (Pubitemid 46151063)
21. Roulot D, Czernichow S, Le Clesiau H, Costes JL, Vergnaud AC, Beaugrand M,. Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. J Hepatol 2008; 48: 606-613.
22. Castera L, Forns X, Alberti A,. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48: 835-847.
23. McGovern BH, Ditelberg JS, Taylor LE, et al. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis 2006; 43: 365-372. (Pubitemid 44078910)
24. Guaraldi G, Squillace N, Stentarelli C, et al. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis 2008; 47: 250-257. (Pubitemid 351920629)
25. Haubrich RH, Riddler SA, DiRienzo AG, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 2009; 23: 1109-1118.
26. Bani-Sadr F, Carrat F, Rosenthal E, et al. Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon-ribavirin combination treatment. Clin Infect Dis 2005; 41: 1806-1809. (Pubitemid 41759869)
27. Macias J, Mira JA, Lopez-Cortes LF, et al. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C. Antivir Ther 2006; 11: 839-846. (Pubitemid 44736175)
28. Walker UA, Bauerle J, Laguno M, et al. Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine. Hepatology 2004; 39: 311-317. (Pubitemid 38222171)
29. Bani-Sadr F, Carrat F, Pol S, et al. Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy. J Acquir Immune Defic Syndr 2005; 40: 47-52. (Pubitemid 41233204)
30. Bani-Sadr F, Lapidus N, Rosenthal E, et al. Gamma glutamyl transferase elevation in HIV/Hepatitis C virus-coinfected patients during interferon-ribavirin combination therapy. J Acquir Immune Defic Syndr 2009; 50: 429-430.
31. Maida I, Nunez M, Rios MJ, et al. Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr 2006; 42: 177-182. (Pubitemid 43884712)
32. Merchante N, Pérez-Camacho I, Mira JA, et al. Prevalence and risk factors for abnormal liver stiffness in HIV-infected patients without viral hepatitis coinfection: role of didanosine. Antivir Ther 2010; 15 (5): 753-763.
33. Wang T, Campbell RV, Yi MK, Lemon SM, Weinman SA,. Role of hepatitis C virus core protein in viral-induced mitochondrial dysfunction. J Viral Hepat 2010; 17 (11): 784-793.
34. de Mendoza C, Martin-Carbonero L, Barreiro P, et al. Mitochondrial DNA depletion in HIV-infected patients with chronic hepatitis C and effect of pegylated interferon plus ribavirin therapy. AIDS 2007; 21: 583-588.
35. Merchante N, Rivero A, de LosSantos-Gil I, et al. Insulin resistance is associated with liver stiffness in HIV/HCV co-infected patients. Gut 2009; 58: 1654-1660.
36. Bhagani S,. HIV/hepatitis C co-infection and hepatic fibrosis: looking beyond HIV-associated immune suppression; the contribution of hepatic steatosis and insulin resistance. Gut 2009; 58: 1579-1581.
37. Petta S, Camma C, Di Marco V, et al. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am J Gastroenterol 2008; 103: 1136-1144. (Pubitemid 351677995)
38. Tebas P,. Insulin resistance and diabetes mellitus associated with antiretroviral use in HIV-infected patients: pathogenesis, prevention, and treatment options. J Acquir Immune Defic Syndr 2008; 49 (Suppl. 2): S86-S92.
39. Tien PC, Schneider MF, Cole SR, et al. Antiretroviral therapy exposure and insulin resistance in the women's interagency HIV study. J Acquir Immune Defic Syndr 2008; 49 (4): 369-376.
40. De Wit S, Sabin CA, Weber R, et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care 2008; 31: 1224-1229.
41. Moucari R, Ripault MP, Martinot-Peignoux M, et al. Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4. Gut 2009; 58: 1662-1669.
42. Pineda JA, González J, Ortega E, et al. Prevalence and factors associated with significant liver fibrosis assessed by transient elastometry in HIV/hepatitis C virus-coinfected patients. J Viral Hepat 2010; 17 (10): 714-719.